ANTX AN2 Therapeutics, Inc.
$3.86▲ +6.34%
Healthcare
Other
After hours
$3.86▲ +0.00%
Oct 27, 4:00 PM ET
Volume 239.6K
Avg Volume (10D) 257.7K
Key Metrics & Fundamentals
Market Cap
$145.66M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.00 - 7.19
% vs 50 MA
-22.42%
% vs 200 MA
-3.99%
RSI-14
39.7
MACD Histogram
+0.0100
Beta (1Y vs SPY)
0.48
Free Cash Flow
-$7.00M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$8.90M
COGS
–
Operating Exp
$8.90M
Operating Income
-$8.90M
EBIT
-$8.90M
Pretax Income
-$8.19M
Net Income
-$8.19M
EPS (Diluted)
-0.18
Price & Volume History
Loading chart…
Recent News
AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
Business Wire · Oct 23, 2026 5:00 PM ET
AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms
Business Wire · Oct 21, 2026 7:00 AM ET
AN2 Therapeutics to Participate at Upcoming Investor Conferences
Business Wire · Oct 20, 2026 4:13 PM ET
GSK (LSE:GSK) Deepens Its Drug Pipeline Through Two Research Partnerships
Simply Wall St. · Oct 7, 2026 10:13 PM ET
GSK (LSE:GSK) The Latest Update Raises A Bigger Question
Simply Wall St. · Sep 30, 2026 7:13 AM ET
AN2 Therapeutics Gets Gates Foundation Funding Extension for Tuberculosis Research
MT Newswires · Sep 28, 2026 7:26 AM ET
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
Business Wire · Sep 28, 2026 7:00 AM ET
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
Business Wire · Sep 16, 2026 5:33 PM ET
Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight
GlobeNewswire · Aug 31, 2026 1:00 PM ET
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
Business Wire · Aug 24, 2026 7:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ANTX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.